Capsida Biotherapeutics

Focus: Capsida Biotherapeutics is a clinical-stage AAV gene therapy company founded in 2019, focused on treating rare genetic neurological and neurodegenerative diseases. The company is headquartered in Thousand Oaks, California and operates at the pre-revenue stage with early-phase clinical programs.

Gene Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Capsida Biotherapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Capsida Biotherapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Natural History Study in Pediatric Patients with STXBP1 Encephalopathy with Epilepsy

STXBP1 Encephalopathy with Epilepsy

N/A

Clinical Trials (1)

NCT05462054Natural History Study in Pediatric Patients with STXBP1 Encephalopathy with Epilepsy

N/A

Help build intelligence for Capsida Biotherapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage opportunity in high-value AAV gene therapy space with focused pipeline targeting rare pediatric neurological indications
Two Phase 1/2 programs in clinical development (DEE and GBA1 Parkinson Disease) offer hands-on exposure to translational work
Rare disease focus provides clear unmet medical need and differentiated clinical pathway

Watch Out For

No active job openings listed and minimal hiring activity signal organizational scaling challenges or restricted hiring
Pre-revenue stage with undisclosed funding and cash position creates uncertainty about runway and future capital access
Early clinical stage (Phase 1/2 only) means years away from potential commercialization or revenue inflection

Generated by Claude from Capsida Biotherapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

gene therapy

Developmental and Epileptic Encephalopathy

Phase 1/2

Clinical Trials (1)

NCT06983158A Clinical Trial of CAP-002 Gene Therapy in Pediatric Patients With Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy

Phase 1/2

gene therapy

GBA1 Parkinson Disease

Phase 1/2

Clinical Trials (1)

NCT07011771A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's Disease

Phase 1/2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2019

Portfolio: 3 clinical trials

Top TAs: Neurology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Neurology

2 pipeline

Marketed

Pipeline